New Data Show Efficacy, Safety and Tolerability of Xeplion in Patients with Schizophrenia at Various Stages of the Disease

02-12-2013 Business Wire HealthComments (0)

Janssen PharmaceuticaPharmaceuticalXeplion

Janssen Pharmaceutica NV has announced results of the PALMFlexS study during The German Society for Psychiatry and Psychotherapy, Psychosomatic Medicine and Neurology (DGPPN) congress in Berlin, 27-30 November 2013.1-8 Data showed flexible maintenance dosing* with Xeplion (paliperidone palmitate) was associated with a clinically relevant treatment response, and was well tolerated in both acute and non-acute patients with schizophre

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top